Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
June 4 (Reuters) - Vigil Neuroscience Inc VIGL.O:
VIGIL NEUROSCIENCE PROVIDES UPDATE ON ILUZANEBART PHASE 2 IGNITE TRIAL IN ALSP
VIGIL NEUROSCIENCE INC - ILUZANEBART SHOWS FAVORABLE SAFETY AND TOLERABILITY PROFILE
VIGIL NEUROSCIENCE INC - PHASE 2 LONG-TERM EXTENSION STUDY DISCONTINUED
VIGIL NEUROSCIENCE INC - PHASE 2 IGNITE TRIAL SHOWS NO BENEFICIAL EFFECTS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Netflix Q1 2026 Earnings Preview: After Acquisition Turmoil, Where Is This Streaming Giant’s Growth Confidence?

Why AMD Stock Popped: 12-Day Winning Rally Signals CPU Renaissance in Agentic AI Push

Why Is Ethereum Stalling While Bitcoin Surges? Will It Ever Reach $10,000?

APLD Stock Surge: How CoreWeave Lease Amendments and Delta Forge 1 Milestones De-risk the Bull Case

GPT-Rosalind Sparks CRO Sector Slump: Should Investors Buy the Dip or Exit Amid AI Drug R&D Impact?

Tradingkey








